What happened in this episode?
Joe Rogan interviews Harvard geneticist David Sinclair about ageing biology, gene therapy and the use of AI in drug discovery. Sinclair says a three-gene ‘OSK’ epigenetic reprogramming approach is being tested in an FDA-approved human clinical trial in the eye for glaucoma and other sudden-vision-loss conditions, and claims he witnessed the first patient dosed earlier this year with no adverse events reported so far. He describes a ‘virus-like’ capsule used to deliver the genes and argues ageing reflects loss of cellular ‘identity’ that can be reset.
Sinclair also makes several forward-looking and contested claims: he says his lab has a ‘top secret’ three-part drink cocktail that rejuvenates older mice within four weeks, and suggests reprogramming could restore cognitive performance in animals and possibly retrieve lost memories. He alleges NAION-related sudden blindness has ‘doubled’ in association with GLP-1 drugs, citing Harvard ophthalmologist Joe Rizzo while noting correlation does not prove causation.
On safety, Sinclair says long-term OSK expression did not increase tumours in mice and claims tumours shrank in mice bearing human cancers when the genes were activated, though he does not cite a published paper during the episode. He says AI has dramatically reduced the time needed to screen potential drug candidates, and recounts a 19-year-old using AI to identify evidence for his ‘backup copy of youth’ theory in existing datasets.
The conversation also touches on research funding: Sinclair says his Harvard lab’s federal funding was cut during a dispute between the university and government, pushing the group towards donations. Rogan and Sinclair discuss fasting, exercise, red light therapy, and the social determinants of longevity, including relationship stress and isolation.
